Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New supplement BK329 shows promise for shedding body fat

NCT ID NCT06628791

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a supplement called BK329 can help reduce body fat in adults who are overweight or have obesity. One hundred participants took either BK329 or a placebo for 12 weeks. Researchers measured changes in total body fat, weight, and other health markers to see if BK329 is effective and safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * individuals with a Body Mass Index (BMI) between 23 and 30 kg/m2. * Individuals who have provided written consent on the consent form. Exclusion Criteria: * Subjects with severe cerebrovascular disease (e.g., stroke, cerebral hemorrhage), heart disease (e.g., angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignant tumors within the last 6 months. (However, subjects with a history of these diseases who are clinically stable may participate at the investigator's discretion.) * Uncontrolled hypertensive patients (blood pressure ≥160/100mmHg, measured after 10 minutes of rest). * Diabetic patients with poor blood glucose control (fasting glucose ≥160mg/dL). * Subjects undergoing treatment for hypothyroidism or hyperthyroidism. * Subjects with creatinine levels ≥ 2 times the upper limit of the research institution's normal range. * Subjects with aspartate transaminase or alanine transaminase levels ≥ 3 times the upper limit of the research institution's normal range. * Subjects experiencing severe gastrointestinal symptoms such as heartburn or indigestion (lactose intolerance). * Subjects who have taken weight-altering drugs (absorption inhibitors, appetite suppressants, obesity-related supplements, psychiatric drugs, beta-blockers, diuretics, contraceptives, steroids, or female hormones) within the last month. * Subjects who have participated in commercial weight loss programs within the last 3 months. * Subjects who have participated in or plan to participate in another clinical trial within the last month. * Alcohol abusers. * Subjects who quit smoking within the last 3 months. * Pregnant or breastfeeding women or those planning pregnancy during the trial period. * Subjects with allergies to any components of the study foods. * Subjects deemed inappropriate for the study by the investigator for other reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity and overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pusan National University Yangsan Hospital

    Yangsan, 50612, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.